Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016

Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016
Published Aug 17, 2016
47 pages — Published Aug 17, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016, provides in depth analysis on Matrix Protein 1 (M1 or M) targeted pipeline therapeutics.

The report provides comprehensive information on the Matrix Protein 1 (M1 or M), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Matrix Protein 1 (M1 or M)
- The report reviews Matrix Protein 1 (M1 or M) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics and enlists all their major and minor projects
- The report assesses Matrix Protein 1 (M1 or M) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Matrix Protein 1 (M1 or M) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Matrix Protein 1 (M1 or M)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying k

  
Source:
Document ID
GMDHC0470TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Matrix Protein 1 (M1 or M) Overview61
Therapeutics Development73
  Matrix Protein 1 (M1 or M) Products under Development by Stage of Development71
  Matrix Protein 1 (M1 or M) Products under Development by Therapy Area81
  Matrix Protein 1 (M1 or M) Products under Development by Indication91
Matrix Protein 1 (M1 or M) Pipeline Products Glance103
  Late Stage Products101
  Early Stage Products111
  Unknown Stage Products121
Matrix Protein 1 (M1 or M) Products under Development by Companies132
Matrix Protein 1 (M1 or M) Products under Development by Universities/Institutes152
Matrix Protein 1 (M1 or M) Therapeutics Assessment176
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Matrix Protein 1 (M1 or M) Companies Involved in Therapeutics Development233
  Novavax, Inc.231
  Redbiotec AG241
  Sarepta Therapeutics, Inc.251
Matrix Protein 1 (M1 or M) Drug Profiles2610
  (influenza (virus like particle) + respiratory syncytial virus) vaccine Drug Profile261
  influenza (virus like particle) vaccine Drug Profile271
  influenza (virus like particle, tetravalent) vaccine Drug Profile282
  influenza [serotype A] vaccine Drug Profile301
  influenza [strain A/H7N9] (virus like particle, monovalent) vaccine Drug Profile312
  radavirsen Drug Profile332
  SARS (virus like particle) vaccine Drug Profile351
Matrix Protein 1 (M1 or M) Featured News &Press Releases3610
  Jul 30, 2015: Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP361
  Nov 17, 2014: Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP361
  Oct 29, 2014: U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M371
  Sep 30, 2014: Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate381
  Sep 23, 2014: Novavax H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M Delivers Positive Phase 1/2 Clinical Data381
  Mar 10, 2014: Novavax Reports Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M391
  Jul 29, 2013: Novavax Initiates First Phase 1 Clinical Trial of its A Influenza Vaccine Candidate391
  Jul 08, 2013: GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine401
  Jul 08, 2013: Novavax Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate401
  May 10, 2013: Novavax's H7N9 VLP Influenza Vaccine Enters Animal Testing411
  Feb 27, 2013: Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA411
  Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100421
  Sep 10, 2012: Novavax Delays Testing On New Experimental Flu Vaccine431
  Jul 24, 2012: NOVAVAX Provides Update on Influenza Programs441
  Mar 30, 2012: AVI BioPharma To Present Preclinical Data From Influenza Study At 22nd European Congress Of Clinical Microbiology And Infectious Diseases451
Appendix462
  Methodology461
  Coverage461
  Secondary Research461
  Primary Research461
  Expert Panel Validation461
  Contact Us461
  Disclaimer471

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Matrix-Protein-1-M1-or-M-Pipeline-Review-H2-2016-2088-16414>
  
APA:
Global Markets Direct - Market Research. (2016). Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Matrix-Protein-1-M1-or-M-Pipeline-Review-H2-2016-2088-16414>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.